Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Bioxyne.
RELATED STOCKHEAD STORIES
News
Top 10 at 11: Not a lot of movement, but there’s not a whole lot of news.
Health & Biotech
These are the ASX stocks Morgans thinks can push the health and wellness agenda
Health & Biotech
Bioxyne embraces AI revolution with B2B marketplace JV targeting expansion of Australia’s cannabis industry
News
ASX Small Caps Lunch Wrap: Who else has been left running for their lives this week?
News
ASX Quarterly Wrap: Bioxyne revenue jumps following BLS acquisition, iCandy cash receipts climb
Health & Biotech
MDMA and magic mushrooms have arrived: Australia lets psychs find a new way for happy to fight sad
Health & Biotech
Bioxyne’s Dr Watson brand extends its Amazon footprint into US and Japan
Tech
These tech and pharma stocks are looking to M&A to drive growth in global markets
Health & Biotech
Check Up: M&A activity in healthcare heats up as Aussie biotech Kinoxis attracts $181m from big pharma
Health & Biotech
Stock Insiders: Bioxyne acquires Breathe Life Sciences with consumer favourite brand Dr Watson
Health & Biotech
Just what the doctor ordered for Bioxyne’s Dr Watson brand
Health & Biotech
Bioxyne positions for growth following Breathe Life Sciences acquisition
Health & Biotech
ASX Health Stocks: Memphasys plans in vivo studies in Japan, Canada; ECS sells Tassie assets
News
Market Highlights: Wall St’s big rally, Budget week, and 5 ASX small caps to watch on Monday
Health & Biotech
Check up: 78 biotech companies rocked the boat this week but only one has real news
Health & Biotech
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
Food & Agriculture
